Overview
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
Status:
Completed
Completed
Trial end date:
2009-06-01
2009-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The objective of this study is to compare the efficacy, safety of DU-176b 30mg or DU-176b 15mg versus enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Daiichi Sankyo Co., Ltd.Treatments:
Edoxaban
Enoxaparin
Enoxaparin sodium
Criteria
Inclusion Criteria:1. Patients undergoing unilateral total hip arthroplasty
2. Patients who are 20-84 years olds
Exclusion Criteria:
1. Subjects with risks of hemorrhage
2. Subjects with thromboembolic risks
3. Subjects who weigh less than 40 kg
4. Subjects who are pregnant or suspect pregnancy, or subjects who want to become
pregnant